Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Myopathy Clear all
Recruiting Phase 3 Interventional

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786
View directory record Official record
Conditions
Myositis
Interventions
PF-06823859, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
45
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

NCT03188666
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
REGN2477, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

NCT05695950
View directory record Official record
Conditions
Dermatomyositis
Interventions
GLPG3667, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Scottsdale, Arizona • Upland, California • Kendall, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 4 Interventional Results available

Abatacept in Juvenile Dermatomyositis

NCT02594735
View directory record Official record
Conditions
Dermatomyositis
Interventions
Abatacept
Drug
Lead sponsor
George Washington University
Other
Eligibility
7 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

NCT02279095
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene dose level 1, Palovarotene dose level 2, Palovarotene dose level 3, Palovarotene dose level 4
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Completed No phase listed Observational Results available

Defining Normal Postoperative Magnetic Resonance Imaging After Total Knee Arthroplasty

NCT04821245
View directory record Official record
Conditions
Local Anesthetic Complication, Local Anesthetic Drug Adverse Reaction
Interventions
Not listed
Lead sponsor
Benaroya Research Institute
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Two Different Forms of Marine Oil on Indirect Markers of Muscle Damage and Soreness in Untrained Men

NCT03760757
View directory record Official record
Conditions
Inflammation; Muscle
Interventions
ESPO-572®, PCSO-524®
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis

NCT07823101
View directory record Official record
Conditions
IBM, Inclusion Body Myositis, Myopathy, Myositis, ALS (Amyotrophic Lateral Sclerosis), PLS
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

NCT07111065
View directory record Official record
Conditions
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions
FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
Dietary Supplement
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Not listed No phase listed Observational

Dermatomyositis and Polymyositis Registry

NCT01637064
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Acthar
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
5
States / cities
Phoenix, Arizona • San Diego, California • Columbia, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Not applicable Interventional

ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit

NCT01270269
View directory record Official record
Conditions
Brain Injuries, Dementia, Myopathies, Muscle Disorders
Interventions
Behavioral: Physical and functional rehabilitation, Behavioral: Cognitive, physical, & functional rehabilitation
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

NCT04829773
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene, midazolam
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 22, 2026, 2:34 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT06255028
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Biological · Drug
Lead sponsor
Century Therapeutics, Inc.
Industry
Eligibility
17 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

FT839 in Autoimmune Diseases

NCT07800871
View directory record Official record
Conditions
ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Interventions
FT839
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed No phase listed Observational Results available

Evaluation of Moderate to Severe Influenza Outcomes in Children

NCT02979626
View directory record Official record
Conditions
Influenza, Otitis Media, Lower Resp Tract Infection, Encephalitic Infection, Myositis Viral, Fever
Interventions
Respiratory nasal swab
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 8 Years
Enrollment
1,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Aurora, Colorado • Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Not applicable Interventional

Comparison of Training Load With/Out Blood Flow Restriction Training in Rheumatoid Populations

NCT04309227
View directory record Official record
Conditions
Rheumatoid Arthritis, Myositis, Osteoarthritis, Weakness, Muscle
Interventions
Strength Training
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

NCT05090891
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
INCB000928, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate

NCT01150526
View directory record Official record
Conditions
Healthy
Interventions
CaHMB, HMB Free Acid Gel, Placebo, Placebo Gel Dosage
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Oct 22, 2026, 2:34 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 1 Interventional

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417
View directory record Official record
Conditions
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Interventions
RAY121
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed No phase listed Observational

The CARRA Registry

NCT01697254
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
9,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 22, 2026, 2:34 PM EDT